INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 177 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2015. The put-call ratio across all filers is 1.16 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $59,287,397 | +28.2% | 3,197,810 | -23.5% | 0.00% | +50.0% |
| Q2 2023 | $46,233,277 | +12.7% | 4,180,224 | +36.9% | 0.00% | 0.0% |
| Q1 2023 | $41,022,069 | -47.8% | 3,054,510 | -51.9% | 0.00% | 0.0% |
| Q4 2022 | $78,572,384 | +84.6% | 6,351,850 | +108.1% | 0.00% | -33.3% |
| Q3 2022 | $42,570,000 | -11.3% | 3,051,584 | -12.2% | 0.00% | 0.0% |
| Q2 2022 | $48,012,000 | -8.4% | 3,476,632 | +7.9% | 0.00% | 0.0% |
| Q1 2022 | $52,419,000 | -1.1% | 3,221,832 | -1.0% | 0.00% | 0.0% |
| Q4 2021 | $53,012,000 | +13.5% | 3,254,266 | +3.5% | 0.00% | +50.0% |
| Q3 2021 | $46,710,000 | -12.0% | 3,145,441 | +18.4% | 0.00% | -33.3% |
| Q2 2021 | $53,052,000 | -18.9% | 2,656,584 | -6.3% | 0.00% | -25.0% |
| Q1 2021 | $65,440,000 | +3.9% | 2,835,342 | +11.2% | 0.00% | 0.0% |
| Q4 2020 | $63,004,000 | -10.1% | 2,550,750 | +50.9% | 0.00% | -20.0% |
| Q3 2020 | $70,070,000 | +16.6% | 1,690,053 | +34.7% | 0.01% | +25.0% |
| Q2 2020 | $60,096,000 | -17.4% | 1,254,351 | +8.5% | 0.00% | -33.3% |
| Q1 2020 | $72,769,000 | -49.1% | 1,155,799 | +0.2% | 0.01% | -40.0% |
| Q4 2019 | $142,896,000 | +47.5% | 1,153,131 | -21.0% | 0.01% | +42.9% |
| Q3 2019 | $96,910,000 | -2.1% | 1,460,366 | +17.4% | 0.01% | 0.0% |
| Q2 2019 | $98,968,000 | -21.1% | 1,243,786 | +11.0% | 0.01% | -30.0% |
| Q1 2019 | $125,363,000 | +34.1% | 1,120,714 | +20.9% | 0.01% | +11.1% |
| Q4 2018 | $93,462,000 | -26.8% | 927,297 | -8.3% | 0.01% | -10.0% |
| Q3 2018 | $127,745,000 | +14.6% | 1,010,966 | -23.9% | 0.01% | +11.1% |
| Q2 2018 | $111,467,000 | +29.7% | 1,328,409 | -4.9% | 0.01% | +28.6% |
| Q1 2018 | $85,948,000 | +17.6% | 1,397,055 | +11.6% | 0.01% | +16.7% |
| Q4 2017 | $73,108,000 | +40.0% | 1,251,401 | +39.0% | 0.01% | +20.0% |
| Q3 2017 | $52,236,000 | -42.4% | 900,003 | +20.1% | 0.01% | -37.5% |
| Q2 2017 | $90,747,000 | -0.4% | 749,572 | -6.9% | 0.01% | 0.0% |
| Q1 2017 | $91,110,000 | +11.7% | 805,550 | +7.3% | 0.01% | 0.0% |
| Q4 2016 | $81,600,000 | -20.7% | 751,027 | +20.2% | 0.01% | -20.0% |
| Q3 2016 | $102,864,000 | +38.5% | 625,016 | +20.1% | 0.01% | +25.0% |
| Q2 2016 | $74,274,000 | +10.9% | 520,567 | -0.2% | 0.01% | +14.3% |
| Q1 2016 | $66,990,000 | +9.7% | 521,407 | +27.5% | 0.01% | 0.0% |
| Q4 2015 | $61,084,000 | +15.9% | 408,976 | +28.7% | 0.01% | +16.7% |
| Q3 2015 | $52,712,000 | -18.7% | 317,787 | +18.2% | 0.01% | -14.3% |
| Q2 2015 | $64,867,000 | +0.7% | 268,751 | +17.6% | 0.01% | 0.0% |
| Q1 2015 | $64,420,000 | +55.8% | 228,463 | -13.8% | 0.01% | +75.0% |
| Q4 2014 | $41,356,000 | -11.5% | 265,086 | +34.3% | 0.00% | -20.0% |
| Q3 2014 | $46,708,000 | +12.2% | 197,329 | +12.2% | 0.01% | +25.0% |
| Q2 2014 | $41,631,000 | -23.9% | 175,917 | +6.0% | 0.00% | -33.3% |
| Q1 2014 | $54,723,000 | +116.0% | 165,933 | -58.2% | 0.01% | +200.0% |
| Q4 2013 | $25,336,000 | +292.4% | 397,185 | +324.8% | 0.00% | +100.0% |
| Q3 2013 | $6,457,000 | +135.7% | 93,490 | +53.0% | 0.00% | – |
| Q2 2013 | $2,740,000 | – | 61,106 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |